Yuichi Iwaki, M.D., Ph.D.
President and Chief Executive Officer, and Founder
Dr. Iwaki holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. He is also a visiting professor at the Nihon University School of Medicine, Kyushu University and Toho University, School of Medicine in Japan. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. He received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of 200 peer-reviewed publications and more than 40 books. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a board member of several biotechnology companies.
Kazuko Matsuda, M.D., Ph.D, MPH
Chief Medical Officer
Dr. Matsuda has served as Vice President of Clinical Development for MediciNova since 2010 and is responsible for all clinical development. Previously, Dr. Matsuda was a clinical advisor to MediciNova for its MN-221 and MN-166 development programs. Prior to joining MediciNova, Dr. Matsuda was assistant professor, University of Southern California, Keck School of Medicine after an appointment at the Children’s Hospital Los Angeles. Dr. Matsuda commenced her residency in internal medicine/pediatrics at Michigan State University and completed a pediatric residency at Loma Linda University. She is a board certified pediatrician in both the United States and Japan. Dr. Matsuda received her M.D. and Ph.D. from Sapporo Medical School and MPH from Harvard University, School of Public Health.
Geoffrey O’Brien, JD/MBA
Vice President and Executive Officer
Mr. O’Brien joined MediciNova in June 2009. Prior to joining MediciNova, Mr. O’Brien worked on Wall Street for 10 years as an equity research analyst and investment banker covering pharmaceutical and biotechnology companies at UBS, DLJ/Credit Suisse First Boston, Nomura, and Punk Ziegel, and was a Vice President from 2004-2008. During his career as a senior equity research analyst on the sell side and buy side, he focused on clinical, scientific, financial, strategic and competitive analysis of development programs and marketed products. He used this analysis to predict the future prospects of both development-stage and established pharmaceutical and biotechnology companies. At UBS, Mr. O’Brien worked on the specialty pharmaceuticals team, which was ranked #2 in Institutional Investor magazine’s All-America Research Team survey. He executed acquisitions and equity offerings as a health care investment banker at DLJ/Credit Suisse First Boston. Prior to graduate school, Mr. O’Brien worked on the successful development of a biotechnology product at The Liposome Company. Mr. O’Brien received a B.S. in chemistry, cum laude, from the University of Delaware and completed his J.D. and M.B.A. simultaneously at Vanderbilt Law School and Owen Graduate School of Management at Vanderbilt University.
Vice President and Head of Japanese Office
Mr. Okajima joined MediciNova in September 2006. Before joining MediciNova, Mr. Okajima served as Deputy General Manager, Daiwa Securities SMBC Co., Ltd. From 1999 through 2002, Mr. Okajima served as Manager, Daiwa Securities’ SB Capital Markets Co., Ltd. (currently Daiwa Securities SMBC Co., Ltd.). As Deputy General Manager, Mr Okajima was involved in pivotal phases of initial public offerings, subsequent public offerings, corporate bond issuances, and mergers & acquisitions. In addition, he handled Investors Relations and stock trading. From 1996 to 1999, Mr. Okajima served as Manager, Sumitomo Capital Securities Co., Ltd. Mr. Okajima served in various positions at Sumitomo Bank, Ltd. (currently Mitsui Sumitomo Bank) between 1991 and 1996. Mr. Okajima graduated with a B.S. Degree from the Department of Science and Technology, Tokyo Science University.
Chief Financial Officer
Ms. Reyes was appointed our Chief Financial Officer effective June 1, 2018. Ms. Reyes joined the accounting services firm of Signature Analytics in May 2018. From August 2013 to May 2018, Ms. Reyes served as Accounting Manager at Rady Children’s Hospital-San Diego, where she was responsible for financial reporting, grants and contracts, and philanthropy accounting. Prior to this, Ms. Reyes served as Senior Manager of Business Processes at Cricket Communications, a wireless service provider, from May 2009 to August 2013. Earlier in her career, Ms. Reyes served in accounting and public reporting roles at SAIC, NextWave and Quest Software. Ms. Reyes received a Bachelor of Accountancy and an MBA from the University of San Diego.